Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cefoxitin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 2.103 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 1.051 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis , and clostridium species. (4) gynecological infections , including endometritis, pelvi

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g in 50 ml - cefoxitin for injection and dextrose injection is indicated for the treatment of lower respiratory tract infections, including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli , klebsiella species, haemophilus influenzae , and bacteroides species. cefoxitin for injection and dextrose injection is indicated for the treatment of urinary tract infections caused by escherichia coli , klebsiella species, proteus mirabilis , morganella morganii , proteus vulgaris and providencia species (including p. rettgeri ). cefoxitin for injection and dextrose injection is indicated for the treatment of intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis , and clostridium species. cefoxi

United States - English - NLM (National Library of Medicine)

samson medical technologies llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 100 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefoxitin and other antibacterial drugs, cefoxitin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. - lower respiratory tract infections, including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections , including endometritis,

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections , including endometritis,

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin sodium 1 g in 10 ml - cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections, including endometritis, pelvic cell

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli , klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli , klebsiella species, proteus mirabilis , morganella morganii , proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by escherichia coli , klebsiella species, bacteroides species including bacteroides fragilis , and clostridium species. (4) gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by escherichia coli , neisseria gonorrhoeae (including penicillinase-producing strains), bacteroides species including b. fragilis , clostridium species, peptococcus niger , peptostreptococcus species, and streptococcus agalactiae . cefoxitin for injection, usp, like cephalosporins, has no activity against chlamydia trachomatis . therefore, when cefoxitin for injection, usp is used in the treatment of patients with pelvic inflammatory disease and c. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) septicemia caused by streptococcus pneumoniae , staphylococcus aureus (including penicillinase-producing strains), escherichia coli , klebsiella species, and bacteroides species including b. fragilis. (6) bone and joint infections caused by staphylococcus aureus (including penicillinase-producing strains). (7) skin and skin structure infections caused by staphylococcus aureus (including penicillinase-producing strains), staphylococcus epidermidis , streptococcus pyogenes and other streptococci (excluding enterococci e.g., enterococcus faecalis [formerly streptococcus faecalis ]), escherichia coli , proteus mirabilis , klebsiella species, bacteroides species including b. fragilis , clostridium species, peptococcus niger , and peptostreptococcus species. appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to cefoxitin for injection, usp. therapy may be started while awaiting the results of these studies. in randomized comparative studies, cefoxitin for injection, usp and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. cefoxitin for injection, usp has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin for injection, usp. similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin g) respond to treatment with cefoxitin for injection, usp. many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin for injection, usp. cefoxitin for injection, usp is indicated for the prophylaxis of infection in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy, abdominal hysterectomy, or cesarean section. if there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate treatment may be instituted. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefoxitin for injection, usp and other antibacterial drugs, cefoxitin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefoxitin for injection is contraindicated in patients who have shown hypersensitivity to cefoxitin and the cephalosporin group of antibiotics.